{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:33:49Z","timestamp":1791923629076,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jad.2024.05.067","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T21:53:20Z","timestamp":1716155600000},"page":"364-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The role of KCNQ channel activators in management of major depressive disorder"],"prefix":"10.1016","volume":"359","author":[{"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jad.2024.05.067_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb1000","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/01.jcp.0000236661.95200.3e","article-title":"An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients","volume":"26","author":"Amann","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2024.05.067_bb0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17460441.2014.892071","article-title":"Fresh approaches to antidepressant drug discovery","volume":"9","author":"Anacker","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1073858420974336","article-title":"Monoamines: dopamine, norepinephrine, and serotonin, beyond modulation,\u201cSwitches\u201d that alter the state of target networks","volume":"28","author":"Azizi","year":"2022","journal-title":"Neuroscientist"},{"issue":"7","key":"10.1016\/j.jad.2024.05.067_bb0025","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000343739.72081.4e","article-title":"Potassium channels: brief overview and implications in epilepsy","volume":"72","author":"Benarroch","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jad.2024.05.067_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eurpsy.2012.02.006","article-title":"Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review","volume":"28","author":"Bersani","year":"2013","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.05.067_bb0035","first-page":"64","article-title":"Phytochemistry and pharmacological aspects of apigenin: a review","volume":"13","author":"Bhardawaj","year":"2023","journal-title":"Nat. Prod. J."},{"issue":"20","key":"10.1016\/j.jad.2024.05.067_bb0040","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jad.2024.05.067_bb0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.jad.2024.05.067_bb0050","first-page":"11","article-title":"Monoamine dysfunction and the pathophysiology and treatment of depression","volume":"59","author":"Charney","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"7433","key":"10.1016\/j.jad.2024.05.067_bb0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11713","article-title":"Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons","volume":"493","author":"Chaudhury","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jad.2024.05.067_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15622975.2021.1939154","article-title":"Microglia and HPA axis in depression: an overview of participation and relationship","volume":"23","author":"Cheiran Pereira","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/appi.ajp.2020.20050653","article-title":"Impact of the KCNQ2\/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial","volume":"178","author":"Costi","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2024.05.067_bb0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2215-0366(20)30036-5","article-title":"Treatment outcomes for depression: challenges and opportunities","volume":"7","author":"Cuijpers","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jad.2020.09.065","article-title":"Depression reported by US adults in 2017\u20132018 and March and April 2020","volume":"278","author":"Daly","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jad.2024.05.067_bb0080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrn1785","article-title":"Pathways modulating neural KCNQ\/M (Kv7) potassium channels","volume":"6","author":"Delmas","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.jad.2024.05.067_bb0085","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/ner.13356","article-title":"Sweetspot mapping in deep brain stimulation: strengths and limitations of current approaches","volume":"25","author":"Dembek","year":"2022","journal-title":"Neuromodulation Technol. Neural Interface"},{"issue":"1","key":"10.1016\/j.jad.2024.05.067_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2007.09.023","article-title":"Effect of the new antiepileptic drug retigabine in a rodent model of mania","volume":"12","author":"Dencker","year":"2008","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.jad.2024.05.067_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuroscience.2019.03.003","article-title":"Reversal of a treatment-resistant, depression-related brain state with the Kv7 channel opener retigabine","volume":"406","author":"Feng","year":"2019","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.jad.2024.05.067_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"Jama"},{"issue":"18","key":"10.1016\/j.jad.2024.05.067_bb0110","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"issue":"6181","key":"10.1016\/j.jad.2024.05.067_bb0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1126\/science.1249240","article-title":"Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience","volume":"344","author":"Friedman","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jad.2024.05.067_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11671","article-title":"KCNQ channel openers reverse depressive symptoms via an active resilience mechanism","volume":"7","author":"Friedman","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jad.2024.05.067_bb0125","first-page":"336","article-title":"The ROCK inhibitor fasudil prevents chronic restraint stress-induced depressive-like behaviors and dendritic spine loss in rat hippocampus","volume":"20","author":"Garc\u00eda-Rojo","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14728222.12.5.565","article-title":"The therapeutic potential of neuronal Kv7 (KCNQ) channel modulators: an update","volume":"12","author":"Gribkoff","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1\u20133","key":"10.1016\/j.jad.2024.05.067_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2007.05.029","article-title":"The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine","volume":"570","author":"Hansen","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"01","key":"10.1016\/j.jad.2024.05.067_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-2007-979535","article-title":"The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans","volume":"29","author":"Heninger","year":"1996","journal-title":"Pharmacopsychiatry"},{"issue":"10328","key":"10.1016\/j.jad.2024.05.067_bb2000","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","article-title":"Time for united action on depression: a Lancet\u2013World Psychiatric Association Commission","volume":"399","author":"Herrman","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jad.2024.05.067_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamapsychiatry.2020.4364","article-title":"Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis","volume":"78","author":"Karyotaki","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2024.05.067_bb0155","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cpt.1096","article-title":"Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial","volume":"104","author":"Kovalchuk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cell.2007.09.018","article-title":"Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions","volume":"131","author":"Krishnan","year":"2007","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.jad.2024.05.067_bb0165","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.14026","article-title":"Selective targeting of M-type potassium Kv7. 4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression-like behaviour","volume":"174","author":"Li","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.jad.2024.05.067_bb0170","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat. Mental Health"},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb0175","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.108.049825","article-title":"Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention","volume":"74","author":"Mackie","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.05.067_bb0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s42003-023-05021-8","article-title":"Ancient medicinal plant rosemary contains a highly efficacious and isoform-selective KCNQ potassium channel opener","volume":"6","author":"Manville","year":"2023","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.05.067_bb0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0195","article-title":"Oral ketamine for depression: an updated systematic review","volume":"1-3","author":"Meshkat","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115709","article-title":"Temporal associations of BMI and glucose parameters with depressive symptoms among US adults","volume":"332","author":"Meshkat","year":"2024","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.jad.2024.05.067_bb0205","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1517\/14656566.2012.706278","article-title":"Retigabine\/Ezogabine, a KCNQ\/KV7 channel opener: pharmacological and clinical data","volume":"13","author":"Orhan","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"issue":"17","key":"10.1016\/j.jad.2024.05.067_bb0210","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1523\/JNEUROSCI.2767-17.2018","article-title":"Restoration of Kv7 channel-mediated inhibition reduces cued-reinstatement of cocaine seeking","volume":"38","author":"Parrilla-Carrero","year":"2018","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.jad.2024.05.067_bb0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/13607860701529635","article-title":"Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis","volume":"11","author":"Pinquart","year":"2007","journal-title":"Aging Ment. Health"},{"issue":"12","key":"10.1016\/j.jad.2024.05.067_bb0220","doi-asserted-by":"crossref","first-page":"20091","DOI":"10.3390\/molecules191220091","article-title":"The chemistry of curcumin: from extraction to therapeutic agent","volume":"19","author":"Priyadarsini","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.jad.2024.05.067_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173590","article-title":"Retigabine promotes ketamine\u2019s antidepressant effect in the forced swim test in male and female C57BL\/6J mice","volume":"230","author":"Qin","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.jad.2024.05.067_bb0230","first-page":"1100","article-title":"Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders","volume":"23","author":"Rahbardar","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.jad.2024.05.067_bb0235","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-pharmtox-052120-104249","article-title":"KCNQ potassium channels as targets of botanical folk medicines","volume":"62","author":"Redford","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0240","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bbr.2008.12.027","article-title":"Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania","volume":"198","author":"Redrobe","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.jad.2024.05.067_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2003.013938","article-title":"Novel mutations in the KCNQ2 gene link epilepsy to a dysfunction of the KCNQ2-calmodulin interaction","volume":"41","author":"Richards","year":"2004","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.jad.2024.05.067_bb0250","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/jpet.108.146944","article-title":"Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl) carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission","volume":"328","author":"Sotty","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.jad.2024.05.067_bb0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1176\/appi.ajp.2020.20030280","article-title":"Toward circuit mechanisms of pathophysiology in depression","volume":"177","author":"Spellman","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.067_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175207","article-title":"Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia","volume":"931","author":"Takase","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jad.2024.05.067_bb0265","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41380-018-0283-2","article-title":"Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder","volume":"25","author":"Tan","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0270","doi-asserted-by":"crossref","first-page":"361","DOI":"10.47162\/RJME.61.2.06","article-title":"Brain changes in depression","volume":"61","author":"Trifu","year":"2020","journal-title":"Romanian J. Morphol. Embryol."},{"issue":"15","key":"10.1016\/j.jad.2024.05.067_bb0275","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/jm034073f","article-title":"(S)N[1-(3-morpholin-4-ylphenyl) ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine","volume":"46","author":"Wu","year":"2003","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2007.11.010","article-title":"Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds","volume":"29","author":"Xiong","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jad.2024.05.067_bb3000","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.jad.2024.05.067_bb0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.yebeh.2013.02.029","article-title":"Ezogabine (KCNQ2\/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression","volume":"28","author":"Zhang","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jad.2024.05.067_bb0290","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2015.11.017","article-title":"Does retigabine affect the development of alcohol dependence?\u2014A pharmaco-EEG study","volume":"611","author":"Zwierzy\u0144ska","year":"2016","journal-title":"Neurosci. Lett."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724008036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724008036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:22:42Z","timestamp":1737667362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724008036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":61,"alternative-id":["S0165032724008036"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.05.067","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of KCNQ channel activators in management of major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}